enGene Therapeutics Inc. (ENGN) › Capital ExpendituresenGene Therapeutics Inc. (ENGN) — Capital ExpendituresAnnual figures by period end, from SEC filings.2022-10-31: $153.0K2023-10-31: $318.0K2024-10-31: $925.0K2025-10-31: $1.49M$1.49M2022-10-31Capital Expenditures (USD)2025-10-31Period endedCapital ExpendituresChange YoYSource filing2025-10-31$1.49M+60.5%2025-12-22From 2024-11-012024-10-31$925.0K+190.9%2025-12-22From 2023-11-012023-10-31$318.0K+107.8%2024-12-19From 2022-11-012022-10-31$153.0K—2024-01-29From 2021-11-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)